Overview of serpin B9 and its roles in cancer (Review)
- Authors:
- Wen-Jun Wang
- Jiao Wang
- Chao Ouyang
- Chong Chen
- Xiao-Feng Xu
- Xiao-Qun Ye
-
Affiliations: Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Respiratory Diseases, Jiujiang First People's Hospital, Jiujiang, Jiangxi 332000, P.R. China - Published online on: July 12, 2021 https://doi.org/10.3892/or.2021.8141
- Article Number: 190
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Feng RM, Zong YN, Cao SM and Xu RH: Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 39:222019. View Article : Google Scholar : PubMed/NCBI | |
|
Hausman DM: What Is Cancer? Perspect Biol Med. 62:778–784. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, et al: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35 (Suppl):S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Qin A, Coffey DG, Warren EH and Ramnath N: Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med. 5:2567–2578. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, et al: Direct tumor killing and immunotherapy through Anti-SerpinB9 therapy. Cell. 183:1219–1233.e18. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lucas A, Yaron JR, Zhang L and Ambadapadi S: Overview of serpins and their roles in biological systems. Methods Mol Biol. 1826:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Singh P and Jairajpuri MA: Structure function analysis of serpin super-family: ‘a computational approach’. Protein Pept Lett. 21:714–721. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI and Whisstock JC: An overview of the serpin superfamily. Genome Biol. 7:2162006. View Article : Google Scholar : PubMed/NCBI | |
|
van Gent D, Sharp P, Morgan K and Kalsheker N: Serpins: Structure, function and molecular evolution. Int J Biochem Cell Biol. 35:1536–1547. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gatto M, Iaccarino L, Ghirardello A, Bassi N, Pontisso P, Punzi L, Shoenfeld Y and Doria A: Serpins, immunity and autoimmunity: Old molecules, new functions. Clin Rev Allergy Immunol. 45:267–280. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Marijanovic EM, Fodor J, Riley BT, Porebski BT, Costa M, Kass I, Hoke DE, McGowan S and Buckle AM: Reactive centre loop dynamics and serpin specificity. Sci Rep. 9:38702019. View Article : Google Scholar : PubMed/NCBI | |
|
Olson ST and Gettins PG: Regulation of proteases by protein inhibitors of the serpin superfamily. Prog Mol Biol Transl Sci. 99:185–240. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rashid Q, Kapil C, Singh P, Kumari V and Jairajpuri MA: Understanding the specificity of serpin-protease complexes through interface analysis. J Biomol Struct Dyn. 33:1352–1362. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kaiserman D and Bird PI: Control of granzymes by serpins. Cell Death Differ. 17:586–595. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pike RN, Bottomley SP, Irving JA, Bird PI and Whisstock JC: Serpins: Finely balanced conformational traps. Iubmb Life. 54:1–7. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Huntington JA, Read RJ and Carrell RW: Structure of a serpin-protease complex shows inhibition by deformation. Nature. 407:923–926. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Huntington JA: Serpin structure, function and dysfunction. J Thromb Haemost. 9 (Suppl 1):S26–S34. 2011. View Article : Google Scholar | |
|
Zheng D, Chen H, Davids J, Bryant M and Lucas A: Serpins for diagnosis and therapy in cancer. Cardiovasc Hematol Disord Drug Targets. 13:123–132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Utaijaratrasmi P, Vaeteewoottacharn K, Tsunematsu T, Jamjantra P, Wongkham S, Pairojkul C, Khuntikeo N, Ishimaru N, Sirivatanauksorn Y, Pongpaibul A, et al: The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells. Mol Cancer. 17:102018. View Article : Google Scholar : PubMed/NCBI | |
|
Gettins PG: Serpin structure, mechanism, and function. Chem Rev. 102:4751–4804. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pontisso P: Role of SERPINB3 in hepatocellular carcinoma. Ann Hepatol. 13:722–727. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hong H, Zhou T, Fang S, Jia M, Xu Z, Dai Z, Li C, Li S, Li L, Zhang T, et al: Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin. Breast Cancer Res Treat. 148:61–72. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT, Zhang GQ and Pang D: Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol. 136:1719–1727. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Silverman GA, Whisstock JC, Askew DJ, Pak SC, Luke CJ, Cataltepe S, Irving JA and Bird PI: Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell Mol Life Sci. 61:301–325. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Izuhara K, Ohta S, Kanaji S, Shiraishi H and Arima K: Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family. Cell Mol Life Sci. 65:2541–2553. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Eyre HJ, Sun J, Sutherland GR and Bird P: Chromosomal mapping of the gene (PI9) encoding the intracellular serpin proteinase inhibitor 9 to 6p25 by fluorescence in situ hybridization. Genomics. 37:406–408. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA, Trapani JA and Bird PI: A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem. 271:27802–27809. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Sprecher CA, Morgenstern KA, Mathewes S, Dahlen JR, Schrader SK, Foster DC and Kisiel W: Molecular cloning, expression, and partial characterization of two novel members of the ovalbumin family of serine proteinase inhibitors. J Biol Chem. 270:29854–29861. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S, Trapani JA and Bird PI: Selective regulation of apoptosis: The cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol. 18:6387–6398. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Trapani JA and Sutton VR: Granzyme B: Pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol. 15:533–543. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, Wang CR, Peter ME and Ashton-Rickardt PG: Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity. 24:451–461. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ansari AW, Temblay JN, Alyahya SH and Ashton-Rickardt PG: Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage. J Immunol. 185:877–883. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Andrew KA, Simkins HM, Witzel S, Perret R, Hudson J, Hermans IF, Ritchie DS, Yang J and Ronchese F: Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol. 181:8356–8362. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lovo E, Zhang M, Wang L and Ashton-Rickardt PG: Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J Immunol. 188:1057–1063. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mangan MS, Vega-Ramos J, Joeckel LT, Mitchell AJ, Rizzitelli A, Roediger B, Kaiserman D, Weninger WW, Villadangos JA and Bird PI: Serpinb9 is a marker of antigen cross-presenting dendritic cells. Mol Immunol. 82:50–56. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Classen CF, Bird PI and Debatin KM: Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol. 143:534–542. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ, Hack CE and Kummer JA: The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol. 166:3218–3225. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Young JL, Sukhova GK, Foster D, Kisiel W, Libby P and Schönbeck U: The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med. 191:1535–1544. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Rowshani AT, Florquin S, Bemelman F, Kummer JA, Hack CE and Ten BI: Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: A potential mechanism for stable renal function in patients with subclinical rejection. Kidney Int. 66:1417–1422. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rowshani AT, Strik MC, Molenaar R, Yong SL, Wolbink AM, Bemelman FJ, Hack CE and Ten BI: The granzyme B inhibitor SERPINB9 (protease inhibitor 9) circulates in blood and increases on primary cytomegalovirus infection after renal transplantation. J Infect Dis. 192:1908–1911. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lau A, Khan K, Pavlosky A, Yin Z, Huang X, Haig A, Liu W, Singh B, Zhang ZX and Jevnikar AM: Serine protease inhibitor-6 inhibits granzyme B-mediated injury of renal tubular cells and promotes renal allograft survival. Transplantation. 98:402–410. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sanad EF, Hamdy NM, El-Etriby AK, Sebak SA and El-Mesallamy HO: Peripheral leucocytes and tissue gene expression of granzyme B/perforin system and serpinB9: Impact on inflammation and insulin resistance in coronary atherosclerosis. Diabetes Res Clin Pract. 131:132–141. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Heutinck KM, Kassies J, Florquin S, Ten BI, Hamann J and Rowshani AT: SerpinB9 expression in human renal tubular epithelial cells is induced by triggering of the viral dsRNA sensors TLR3, MDA5 and RIG-I. Nephrol Dial Transplant. 27:2746–2754. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
van der Burgh R, Meeldijk J, Jongeneel L, Frenkel J, Bovenschen N, van Gijn M and Boes M: Reduced serpinB9-mediated caspase-1 inhibition can contribute to autoinflammatory disease. Oncotarget. 7:19265–19271. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kaartokallio T, Cervera A, Kyllönen A, Laivuori K, Kere J and Laivuori H: Gene expression profiling of pre-eclamptic placentae by RNA sequencing. Sci Rep. 5:141072015. View Article : Google Scholar : PubMed/NCBI | |
|
Ten BR, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ and Oudejans JJ: Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood. 99:4540–4546. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pohjanen VM, Kokkonen TS, Arvonen M, Augustin MA, Patankar M, Turunen S, Vähäsalo P and Karttunen TJ: Decreased expression of protease inhibitor 9, a granzyme B inhibitor, in celiac disease: A potential mechanism in enterocyte destruction and villous atrophy. Int J Immunopathol Pharmacol. 26:897–905. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Vycital O, Pitule P, Hosek P, Kriz T, Treska V and Liska V: Expression of serpin B9 as a prognostic factor of colorectal cancer. Anticancer Res. 39:6063–6066. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
McCorkle JR, Leonard MK, Kraner SD, Blalock EM, Ma D, Zimmer SG and Kaetzel DM: The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma. Cancer Genomics Proteomics. 11:175–194. 2014.PubMed/NCBI | |
|
Ferreri AJ, Govi S, Pileri SA and Savage KJ: Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 85:206–215. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bots M, Offringa R and Medema JP: Does the serpin PI-9 protect tumor cells? Blood. 107:4974–4975, 4975. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Luo H and Ma C: Identification of prognostic genes in uveal melanoma microenvironment. PLoS One. 15:e2422632020. View Article : Google Scholar | |
|
Zhou B, Chen E, Chen J, Zhang J, Zhang N and Chen Z: Overexpression of proteinase inhibitor 9 is associated with poor prognosis in human hepatocellular carcinoma and with proliferation and apoptosis in HepG2 cells in vitro. Int J Clin Exp Pathol. 12:3719–3727. 2019.PubMed/NCBI | |
|
Schiffer S, Hansen HP, Hehmann-Titt G, Huhn M, Fischer R, Barth S and Thepen T: Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer J. 3:e1062013. View Article : Google Scholar : PubMed/NCBI | |
|
Peters FS, Peeters A, van den Bosch T, Mooyaart AL, van de Wetering J, Betjes M, Baan CC and Boer K: Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer. Clin Exp Immunol. 197:341–351. 2019.PubMed/NCBI | |
|
Vycital O, Dubova M, Palek R, Hosek P, Branzovsky J, Treska V, Daum O and Liska V: The impact of immune interaction on the metastatic infiltration of colorectal carcinoma to lymph nodes. Anticancer Res. 38:4159–4167. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Repetto O, De Re V, De Paoli A, Belluco C, Alessandrini L, Canzonieri V and Cannizzaro R: Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Oncotarget. 8:28328–28341. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lauricella M, Carlisi D, Giuliano M, Calvaruso G, Cernigliaro C, Vento R and D'Anneo A: The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms. Int J Oncol. 49:352–360. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo LC, Cheng LC, Lee CH, Lin CJ, Chen PY and Li LA: Estrogen and cigarette sidestream smoke particulate matter exhibit ERα-dependent tumor-promoting effects in lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 313:L477–L490. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rousalova I, Krepela E, Prochazka J, Cermak J and Benkova K: Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues. Int J Oncol. 36:275–283. 2010.PubMed/NCBI | |
|
Tanaka K, Harashima N, Niiya F, Miyagi Y, Hida N, Ochi M, Imai N, Harada M, Itoh K and Shichijo S: Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients. Jpn J Cancer Res. 93:198–208. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kannan-Thulasiraman P and Shapiro DJ: Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J Biol Chem. 277:41230–41239. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Soriano C, Mukaro V, Hodge G, Ahern J, Holmes M, Jersmann H, Moffat D, Meredith D, Jurisevic C, Reynolds PN and Hodge S: Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: Mechanism for immune evasion? Lung Cancer. 77:38–45. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ko YH, Park S, Jin H, Woo H, Lee H, Park C and Kim K: Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma. Lab Invest. 87:241–250. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kummer JA, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R, Strik MC, Hack CE and Tschopp J: Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ. 14:1486–1496. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bots M, Kolfschoten IG, Bres SA, Rademaker MT, de Roo GM, Krüse M, Franken KL, Hahne M, Froelich CJ, Melief CJ, et al: SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. Blood. 105:1153–1161. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lakshmi NB, Eshvendar RK, Shantikumar S and Ramakrishna S: Immune system: A double-edged sword in cancer. Inflamm Res. 62:823–834. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Riley RS, June CH, Langer R and Mitchell MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 18:175–196. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Helmy KY, Patel SA, Nahas GR and Rameshwar P: Cancer immunotherapy: Accomplishments to date and future promise. Ther Deliv. 4:1307–1320. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bladergroen BA, Meijer CJ, Ten BR, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O and Kummer JA: Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: A novel protective mechanism for tumor cells to circumvent the immune system? Blood. 99:232–237. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Choi PJ and Mitchison TJ: Quantitative analysis of resistance to natural killer attacks reveals stepwise killing kinetics. Integr Biol (Camb). 6:1153–1161. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang X, Ellison SJ, Alarid ET and Shapiro DJ: Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene. 26:4106–4114. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang X, Patterson NM, Ling Y, Xie J, Helferich WG and Shapiro DJ: Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. Endocrinology. 149:5366–5373. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Muris JJ, Meijer CJ, Cillessen SA, Vos W, Kummer JA, Bladergroen BA, Bogman MJ, MacKenzie MA, Jiwa NM, Siegenbeek VHL, et al: Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia. 18:589–596. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Tang CH, Sue YM, Hsieh WT, Wang YH and Wang CC: Increased risk of cutaneous squamous cell carcinoma in organ transplant recipients and patients on chronic dialysis: A cancer registry-based study in taiwan. Acta Derm Venereol. 99:1275–1281. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vermeulen JF, van Hecke W, Spliet WG, Villacorta HJ, Fisch P, Broekhuizen R and Bovenschen N: Pediatric primitive neuroectodermal tumors of the central nervous system differentially express granzyme inhibitors. PLoS One. 11:e1514652016. View Article : Google Scholar : PubMed/NCBI | |
|
Buzza MS, Hosking P and Bird PI: The granzyme B inhibitor, PI-9, is differentially expressed during placental development and up-regulated in hydatidiform moles. Placenta. 27:62–69. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ray M, Hostetter DR, Loeb CR, Simko J and Craik CS: Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis. Prostate. 72:846–855. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang X, Orr BA, Kranz DM and Shapiro DJ: Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells. Endocrinology. 147:1419–1426. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bossard C, Belhadj K, Reyes F, Martin-Garcia N, Berger F, Kummer JA, Brière J, Baglin AC, Cheze S, Bosq J, et al: Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: Results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 109:2183–2189. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tse E and Kwong YL: NK/T-cell lymphomas. Best Pract Res Clin Haematol. 32:253–261. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zeeshan R and Mutahir Z: Cancer metastasis-tricks of the trade. Bosn J Basic Med Sci. 17:172–182. 2017.PubMed/NCBI | |
|
Milette S, Hashimoto M, Perrino S, Qi S, Chen M, Ham B, Wang N, Istomine R, Lowy AM, Piccirillo CA and Brodt P: Sexual dimorphism and the role of estrogen in the immune microenvironment of liver metastases. Nat Commun. 10:57452019. View Article : Google Scholar : PubMed/NCBI | |
|
Selicharova I, Sanda M, Mladkova J, Ohri SS, Vashishta A, Fusek M, Jiracek J and Vetvicka V: 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: Comparison with parental cell line MDA-MB-231. Oncol Rep. 19:1237–1244. 2008.PubMed/NCBI | |
|
Vermijlen D, Luo D, Froelich CJ, Medema JP, Kummer JA, Willems E, Braet F and Wisse E: Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol. 72:668–676. 2002.PubMed/NCBI | |
|
Zheng HC: The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sullivan EM, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, Bari R, Schell S, Tuggle M, Pui CH and Leung W: NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 20:5986–5994. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cunningham TD, Jiang X and Shapiro DJ: Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol. 245:32–41. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Baskar R, Lee KA, Yeo R and Yeoh KW: Cancer and radiation therapy: Current advances and future directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Cao Y, Markelc B, Kaeppler J, Vermeer JA and Muschel RJ: Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation. J Clin Invest. 129:4224–4238. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ilienko IM, Golyarnik NA, Lyaskivska OV, Belayev OA and Bazyka DA: Expression of biological markers induced by ionizing radiation at the late period after exposure in a wide range of doses. Probl Radiac Med Radiobiol. 23:331–350. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ and Offringa R: Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA. 98:11515–11520. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Melo AM, Conroy MJ, Foley EK, Dockry É, Breen EP, Reynolds JV, Lysaght J and Doherty DG: CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies. Cancer Immunol Immunother. 69:969–982. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Senju S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Fukushima S, Matsuyoshi H and Nishimura Y: Pluripotent stem cells as source of dendritic cells for immune therapy. Int J Hematol. 91:392–400. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fukuma D, Matsuyoshi H, Hirata S, Kurisaki A, Motomura Y, Yoshitake Y, Shinohara M, Nishimura Y and Senju S: Cancer prevention with semi-allogeneic ES cell-derived dendritic cells. Biochem Biophys Res Commun. 335:5–13. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kuşoğlu A and Biray AÇ: Cancer stem cells: A brief review of the current status. Gene. 681:80–85. 2019. View Article : Google Scholar | |
|
Erkisa M, Karakas D and Ulukaya E: Cancer stem cells: Root of the evil. Crit Rev Oncog. 24:69–87. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
El HN, Heathcote D, Moore R, Yang S, Azzi J, Mfarrej B, Atkinson M, Sayegh MH, Lee JS, Ashton-Rickardt PG and Abdi R: Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood. 117:1176–1183. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Abdullah Z, Saric T, Kashkar H, Baschuk N, Yazdanpanah B, Fleischmann BK, Hescheler J, Krönke M and Utermöhlen O: Serpin-6 expression protects embryonic stem cells from lysis by antigen-specific CTL. J Immunol. 178:3390–3399. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lourenco S, Teixeira VH, Kalber T, Jose RJ, Floto RA and Janes SM: Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol. 194:3463–3474. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A and Rich JN: Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 18:829–840. 2011. View Article : Google Scholar : PubMed/NCBI |
